| |
 |
Therapeutic Expertise |
|
|
 |
|
|
Synarc is continually developing and validating new and proprietary markers for commercial enterprises, academic affiliate groups, and national and global institutes charged with overseeing clinical trials.
We integrate innovative biochemical markers with subject recruitment and centralized medical image analysis to efficiently drive development.
Let our biochemical-marker expertise minimize the time, number of subjects, and financial resources necessary for your next clinical study.
Excellence in biochemical-marker development and application
We strive to develop biochemical markers that can serve as surrogates for key outcome parameters, such as fracture risk, survival, and quality of life. Our in house scientific experts help Synarc clients select the most appropriate biochemical markers for each clinical trial.
Our services combine biochemical markers and imaging results to predict disease progression in a timely and accurate way. We limit measurement variability through our comprehensive and strict quality control program, and we support our clients’ clinical sites with all the resources needed for success.
Improved assessment of efficacy and safety
Our unique biochemical-marker services provide more accurate and precise assessment of efficacy and greater statistical power, which support better-informed and earlier decisions about the course of a clinical trial.
Centralized logistical and supply support
Synarc’s centralized oversight of biochemical-marker studies ensures accurate, rapid, and standardized collection and review of clinical data by our expert medical and scientific staff. Global data management is customized and fully regulatory compliant.
All Synarc biochemicalmarker assays are performed in Lyon, France.
|
|
 |
Biochemical-Marker Services |
| |
| Bone degradation |
- Serum and urine C-telopeptide cross-linking
of type I collagen (CTX-I)
- Serum and urine N-telopeptide cross-linking
of type I collagen (NTX-I)
- Total and free urinary deoxypyridinoline (DPD)
by ELISA and HPLC
- Serum tartrate-resistant acid phosphatase
isoenzyme 5b (TRAcP5b)
- Urinary type I collagen helical peptide
|
| Bone Formation |
- Serum osteocalcin
- Serum bone-specific alkaline phosphatase
- Serum N- and C-terminal propeptides of type I
collagen (PICP, PINP)
|
| Regulators of osteoclastic and osteoblastic activity |
- Serum osteoprotegerin (OPG)
- Serum RANK-L (total and free)
- Serum Dickkopf-1 (Dkk-1)
|
| Cartilage degradation |
- Urine C-telopeptide cross-linking of type II collagen
(CTX-II, CartiLaps®)
- Serum and urinary type II collagen helical peptide
(HELIX-II, Syncart™)
- Serum type II collagenase neoepitopes (C2C, C12C)
- Serum cartilage oligomeric matrix protein (COMP)
|
| Cartilage synthesis and turnover |
- Serum N- and C-terminal propetides of type II
collagen (PIICP, PIIANP)
- Serum aggrecan epitope 846 (CS 846)
- Serum glycosaminoglycan
|
| Synovial activity |
- Urinary glucosyl-galactosyl pyridinoline
(Glc-Gal-PYD, Synomark)
- Serum nitrosylated type III collagen N-telopeptide (IIINys)
- Hyaluronic acid
- YKL-40
- Serum type III N-terminal propeptide (PIIINP)
|
| Matrix-metalloproteases |
- MMP-1, MMP-2, MMP-3, MMP-7, MMP-9, MMP-13
- TIMP-1, TIMP-2
|
| Serum ultrasensitive C-reactive protein |
| Cytokines/chemokines |
| |
|
|
|
|
Download PDF brochure of Synarc services in Biochemical Markers.